Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT03969446 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03969446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03969446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Suspended
Start date
May 4, 2020
Completion date
July 4, 2027
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory myelodysplastic syndrome